Ibrutinib reverses IL-6-induced osimertinib resistance through inhibition of Laminin α5/FAK signaling

FAK Structure and Regulation by Membrane Interactions and Force in Focal Adhesions

(2020) Paula Tapial Martínez et al.   Biomolecules

Mechanisms of osimertinib resistance and emerging treatment options

(2020) Sabine Schmid et al.   LUNG CANCER

Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer

(2020) Yulong Fu et al.   Journal of Hematology & Oncology

Protective autophagy decreases osimertinib cytotoxicity through regulation of stem cell-like properties in lung cancer

(2019) Li Li et al.   CANCER LETTERS

Exon-16-skipping HER2 as a novel mechanism of osimertinib-resistance in EGFR L858R/T790M-positive non-small-cell lung cancer

(2019) Chia-Chi Hsu et al.   Journal of Thoracic Oncology

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

(2019) Suresh S. Ramalingam et al.   NEW ENGLAND JOURNAL OF MEDICINE

Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients

(2018) Zhe Yang et al.   CLINICAL CANCER RESEARCH

Cross-talk between EGFR and IL-6 drives oncogenic signaling and offers therapeutic opportunities in cancer

(2018) Kriti Ray et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Targeting the IL-6/JAK/STAT3 signalling axis in cancer

(2018) Daniel E. Johnson et al.   Nature Reviews Clinical Oncology

Novel Indications for Bruton’s Tyrosine Kinase Inhibitors, beyond Hematological Malignancies

(2018) Robert Campbell et al.   Journal of Clinical Medicine

Impact of serum vascular endothelial growth factor and interleukin-6 on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small-cell lung cancer

(2018) Yijun Jia et al.   LUNG CANCER

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib

(2018) Geoffrey R. Oxnard et al.   JAMA Oncology

STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets

(2018) Damian Szklarczyk et al.   NUCLEIC ACIDS RESEARCH

Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers

(2017) Monique B. Nilsson et al.   Science Translational Medicine

Early Secreted Antigenic Target of 6-kDa of Mycobacterium tuberculosis Stimulates IL-6 Production by Macrophages through Activation of STAT3

(2017) Bock-Gie Jung et al.   Scientific Reports

IL-6 Secreted from Cancer-Associated Fibroblasts Mediates Chemoresistance in NSCLC by Increasing Epithelial-Mesenchymal Transition Signaling

(2016) Yasushi Shintani et al.   Journal of Thoracic Oncology

Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism

(2016) Chengguang Zhao et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation

(2016) Aoli Wang et al.   Oncotarget

Upregulated interleukin-6 expression contributes to erlotinib resistance in head and neck squamous cell carcinoma

(2015) Aditya Stanam et al.   Molecular Oncology

IL-6 as a keystone cytokine in health and disease

(2015) Christopher A Hunter et al.   NATURE IMMUNOLOGY

Metformin Sensitizes EGFR-TKI-Resistant Human Lung Cancer Cells In Vitro and In Vivo through Inhibition of IL-6 Signaling and EMT Reversal

(2014) L. Li et al.   CLINICAL CANCER RESEARCH

Selective Antitumor Activity of Ibrutinib in EGFR-Mutant Non–Small Cell Lung Cancer Cells

(2014) Wen Gao et al.   JNCI-Journal of the National Cancer Institute

IL‐6 Regulates Extracellular Matrix Remodeling Associated With Aortic Dilation in a Fibrillin‐1 Hypomorphic mgR/mgR Mouse Model of Severe Marfan Syndrome

(2014) Xiaoxi Ju et al.   Journal of the American Heart Association

Laminin α5 guides tissue patterning and organogenesis

(2013) Caroline Spenlé et al.   Cell Adhesion & Migration

TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions

(2013) Daehwan Kim et al.   GENOME BIOLOGY

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

(2012) Ranjana H. Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cells

(2012) Tom A. Barr et al.   JOURNAL OF EXPERIMENTAL MEDICINE

clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters

(2012) Guangchuang Yu et al.   OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY

Critical features of FAK-expressing AML bone marrow microenvironment through leukemia stem cell hijacking of mesenchymal stromal cells

(2011) M Despeaux et al.   LEUKEMIA

Signal transduction by focal adhesion kinase in cancer

(2009) Jihe Zhao et al.   CANCER AND METASTASIS REVIEWS

RNA-seq: An assessment of technical reproducibility and comparison with gene expression arrays

(2008) J. C. Marioni et al.   GENOME RESEARCH